Prognosis
Astra Vaccine Woes Grow as Regulators Try to Ease Clot Fears
- Shot once seen as frontrunner now faces halts globally
- Company says no evidence vaccine increases blood-clot risk
This article is for subscribers only.
We're tracking the latest on the coronavirus outbreak and the global response. Sign up here for our daily newsletter on what you need to know.
AstraZeneca Plc’s vaccine for Covid-19, once expected to be a mainstay of protection for much of the world, remains shrouded in controversy as more countries limit its use even as scientists warn of the need for governments to tread carefully.